Literature DB >> 31522599

A homozygote novel L451W mutation in CECR1 gene causes deficiency of adenosine deaminase 2 in a pediatric patient representing with chronic lymphoproliferation and cytopenia.

Rabia Miray Kisla Ekinci1, Sibel Balcı1, Atil Bisgin2, Ilgen Sasmaz3, Goksel Leblebisatan3, Faruk Incecik4, Mustafa Yilmaz1.   

Abstract

Deficiency of Adenosine Deaminase 2 (DADA2) is a monogenic autoinflammatory disorder characterized by livedo reticularis, skin ulcers, subcutaneous rash, aphthous ulcers, and leukocytoclastic vasculitis, neurological signs such as early onset stroke and polyneuropathy. A minority of DADA2 patients suffer from severe cytopenia and lymphoproliferation. Herein, we report an adolescent patient, followed up as having a hematological disorder for many years, eventually diagnosed as having DADA2. In view of the presence of elevated acute phase reactants, hepatosplenomegaly, low IgM level, lymphopenia, anemia, and neutropenia, and a subtle neurological involvement we considered DADA2 diagnosis. The diagnosis was confirmed by identification of a novel L451W mutation in CECR1 gene. The patient has been successfully treated with etanercept, monthly intravenous immunoglobulin replacement, and low-dose methylprednisolone. In conclusion, although the absence of skin and neurological findings, low IgM levels, and persistent lymphopenia should lead the physicians to consider DADA2 in patients with particularly complicated hematological abnormalities.

Entities:  

Keywords:  CECR1 gene; cytopenia deficiency of adenosine deaminase 2; lymphoproliferation

Mesh:

Substances:

Year:  2019        PMID: 31522599     DOI: 10.1080/08880018.2019.1621973

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  4 in total

Review 1.  Deficiency of Human Adenosine Deaminase Type 2 - A Diagnostic Conundrum for the Hematologist.

Authors:  Rakesh Kumar Pilania; Aaqib Zaffar Banday; Saniya Sharma; Rajni Kumrah; Vibhu Joshi; Sathish Loganathan; Manpreet Dhaliwal; Ankur Kumar Jindal; Pandiarajan Vignesh; Deepti Suri; Amit Rawat; Surjit Singh
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

Review 2.  Expanding spectrum of DADA2: a review of phenotypes, genetics, pathogenesis and treatment.

Authors:  Benzeeta Pinto; Prateek Deo; Susmita Sharma; Arshi Syal; Aman Sharma
Journal:  Clin Rheumatol       Date:  2021-03-31       Impact factor: 2.980

3.  Novel Adenosine Deaminase 2 (ADA2) Mutations Associated With Hematological Manifestations.

Authors:  Reem Albalawi; Ehab Hanafy; Haifa Alnafea; Mohammed Altowijiry; Shaima Riyad; Fadwa Abufara; Naif Albolowi
Journal:  J Investig Med High Impact Case Rep       Date:  2021 Jan-Dec

4.  Plasma Adenosine Deaminase (ADA)-1 and -2 Demonstrate Robust Ontogeny Across the First Four Months of Human Life.

Authors:  Oludare A Odumade; Alec L Plotkin; Jensen Pak; Olubukola T Idoko; Matthew A Pettengill; Tobias R Kollmann; Al Ozonoff; Beate Kampmann; Ofer Levy; Kinga K Smolen
Journal:  Front Immunol       Date:  2021-05-27       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.